CagriSema vs Tirzepatide
Novo Nordisk's semaglutide plus cagrilintide combination versus Eli Lilly's GIP/GLP-1 dual agonist tirzepatide.
Last updated: January 28, 2026
CagriSema
Tirzepatide
Overview
CagriSema and tirzepatide represent different pharmaceutical strategies for enhanced weight loss. CagriSema combines two separate peptides (semaglutide and cagrilintide) into a single injection, while tirzepatide is a single molecule with dual receptor activity. Both aim to achieve greater efficacy than GLP-1 monotherapy.
This comparison is significant as it represents competition between the two major players in metabolic medicine: Novo Nordisk and Eli Lilly.
Key Facts
| Aspect | CagriSema | Tirzepatide |
|---|---|---|
| Developer | Novo Nordisk | Eli Lilly |
| Approach | Combination product | Single molecule |
| Targets | GLP-1 + Amylin | GIP + GLP-1 |
| FDA Status | Phase 3 (not approved) | FDA approved |
Mechanism Comparison
| Aspect | CagriSema | Tirzepatide |
|---|---|---|
| GLP-1 Activity | Semaglutide (agonist) | Built-in GLP-1 agonism |
| Second Mechanism | Cagrilintide (amylin analog) | GIP agonism |
| Receptor Targets | GLP-1R + AMY-R | GIPR + GLP-1R |
| Unique Feature | Amylin-based satiety | Novel dual agonist |
CagriSema Components
Semaglutide:
- GLP-1 receptor agonist
- Same as Wegovy/Ozempic
- Reduces appetite, slows gastric emptying
Cagrilintide:
- Long-acting amylin analog
- Enhances satiety signaling
- Slows gastric emptying (additive to GLP-1)
- Novel mechanism not previously combined with GLP-1
Tirzepatide Mechanism
- Single molecule with dual activity
- GIP receptor agonism (primary)
- GLP-1 receptor agonism (secondary)
- Synergistic effects on insulin and appetite
Clinical Trial Data
CagriSema Phase 3 (REDEFINE)
| Trial | Result |
|---|---|
| REDEFINE 1 | ~22.7% weight loss at 68 weeks |
| REDEFINE 2 (T2D) | Ongoing |
| REDEFINE Pivotal | Ongoing |
Note: Phase 3 data released in early 2024 showed strong results.
Tirzepatide Phase 3 (SURMOUNT)
| Trial | Dose | Weight Loss |
|---|---|---|
| SURMOUNT-1 | 15mg | -22.5% |
| SURMOUNT-2 | 15mg | -15.7% (T2D) |
| SURMOUNT-3 | 15mg | -26.6% (after lifestyle) |
| SURMOUNT-4 | 15mg | Maintained vs regain |
Efficacy Comparison
| Outcome | CagriSema | Tirzepatide |
|---|---|---|
| Max Weight Loss | ~22.7% (68 wk) | ~22.5% (72 wk) |
| ≥20% Weight Loss | ~55% | ~57% |
| ≥25% Weight Loss | ~35% | ~36% |
| HbA1c Reduction | TBD | -2.3% |
Important: These are cross-trial comparisons. Direct head-to-head data is not available.
Trial Population Differences
| Factor | REDEFINE 1 | SURMOUNT-1 |
|---|---|---|
| Baseline BMI | ~38 kg/m² | ~38 kg/m² |
| Duration | 68 weeks | 72 weeks |
| Background | No T2D | No T2D |
Side Effect Profile
Gastrointestinal Effects
| Side Effect | CagriSema | Tirzepatide |
|---|---|---|
| Nausea | ~40-45% | ~30-35% |
| Vomiting | ~20-25% | ~15-20% |
| Diarrhea | ~20% | ~20% |
| Constipation | ~15% | ~15% |
Note: CagriSema may have higher initial GI effects due to dual satiety mechanisms.
Discontinuation Rates
| Reason | CagriSema | Tirzepatide |
|---|---|---|
| GI Side Effects | ~6-8% | ~4-7% |
| Overall | ~10-12% | ~6-10% |
Unique Considerations
| Factor | CagriSema | Tirzepatide |
|---|---|---|
| Injection | Single combined | Single |
| Component Flexibility | Fixed ratio | N/A |
| Approved Components | Semaglutide (yes) | Tirzepatide (yes) |
| Amylin Experience | First long-acting combo | No amylin |
Regulatory and Development
| Aspect | CagriSema | Tirzepatide |
|---|---|---|
| Phase | Phase 3 ongoing | Approved |
| Expected Approval | 2025-2026 | Already approved |
| Obesity Approval | Pending | Yes (Zepbound) |
| T2D Approval | Pending | Yes (Mounjaro) |
Commercial Considerations
| Factor | CagriSema | Tirzepatide |
|---|---|---|
| First-mover | No | Yes |
| Brand Recognition | Builds on Wegovy | New brand |
| Manufacturing | Combination complexity | Single molecule |
| Pricing | Unknown | ~$1,000/month |
Evidence Quality
| Factor | CagriSema | Tirzepatide |
|---|---|---|
| Trial Phase | Phase 3 | Phase 3 complete |
| Sample Size | Thousands | Thousands |
| CV Outcomes | Pending | Ongoing (SURPASS-CVOT) |
| Real-World Data | None | Emerging |
| Long-term Safety | Limited | Growing |
Summary
| Factor | CagriSema | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 + Amylin | GIP + GLP-1 |
| Evidence Level | High (Phase 3) | High (approved) |
| Weight Loss | ~22.7% | ~22.5% |
| Unique Strength | Dual satiety pathways | Proven, available |
| Availability | Investigational | FDA approved |
Key Takeaways
- Similar efficacy: Both achieve approximately 22-23% weight loss in Phase 3 trials
- Different mechanisms: CagriSema adds amylin; tirzepatide adds GIP to GLP-1
- Tirzepatide is available: FDA-approved and commercially accessible
- CagriSema is promising: Strong Phase 3 data with novel amylin component
- No head-to-head trial: Cross-trial comparisons have limitations
- GI tolerance: Tirzepatide may have slightly better GI tolerability
- Choice will depend on: Availability, cost, insurance, individual response
This comparison is for educational purposes only. CagriSema is investigational and not approved. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.